Cadrenal Therapeutics, INC. (CVKD) — SEC Filings

Overview

Cadrenal Therapeutics, INC. (CVKD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 1, 2026: Cadrenal Therapeutics, Inc. filed an 8-K on April 1, 2026, reporting a material definitive agreement and unregistered sales of equity securities. The filing includes exhibits detailing forms of new warrants, placement agent warrants, and a warrant inducement agreement, suggesting potential financing

Sentiment Summary

Across 46 filings, the sentiment breakdown is: 5 bearish, 39 neutral, 2 mixed. The dominant filing sentiment for Cadrenal Therapeutics, INC. is neutral.

Filing Type Overview

Cadrenal Therapeutics, INC. (CVKD) has filed 27 8-K, 1 424B5, 3 10-K, 1 S-1, 6 10-Q, 2 DEF 14A, 2 SC 13G/A, 2 SC 13G, 1 DEFA14A, 1 8-K/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (46)

• Cadrenal Therapeutics Files 8-K on Warrants and Equity — 8-K · Apr 1, 2026 Risk: medium
  Cadrenal Therapeutics, Inc. filed an 8-K on April 1, 2026, reporting a material definitive agreement and unregistered sales of equity securities. The filing inc
• Cadrenal Therapeutics Files Prospectus Supplement — 424B5 · Apr 1, 2026 Risk: low
  Cadrenal Therapeutics, Inc. filed a 424B5 form on April 1, 2026, related to a prospectus supplement. The filing details the company's business address and conta
• Cadrenal Pivots to CAD-1005, Eyes Phase 3 for Deadly Blood Disorder — 10-K · Mar 31, 2026 Risk: high
  Cadrenal Therapeutics, Inc. (CVKD) reported a strategic shift in its primary focus to the development of CAD-1005 for immune-mediated and thrombotic disorders,
• 8-K Filing — 8-K · Mar 31, 2026
• Cadrenal Files S-1 for Resale of 428K Shares, Acquires VLX-1005 Asset — S-1 · Dec 29, 2025 Risk: medium
  Cadrenal Therapeutics, Inc. (CVKD) filed an S-1 on December 23, 2025, primarily for the resale of up to 428,227 shares of common stock by Selling Stockholders.
• 8-K Filing — 8-K · Dec 23, 2025
• 8-K Filing — 8-K · Dec 16, 2025
• 8-K Filing — 8-K · Dec 11, 2025
• Cadrenal Therapeutics Announces Executive Changes and Board Updates — 8-K · Dec 1, 2025 Risk: medium
  Cadrenal Therapeutics, Inc. announced on November 24, 2025, the departure of Dr. Michael L. R. Freeman from his role as Chief Medical Officer. The company also
• Cadrenal Therapeutics Files 8-K — 8-K · Nov 18, 2025 Risk: low
  On November 18, 2025, Cadrenal Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 822 A1A Nor
• Cadrenal's Losses Widen, Cash Dwindles Amid Going Concern Doubts — 10-Q · Nov 10, 2025 Risk: high
  Cadrenal Therapeutics, Inc. reported a net loss of $2,685,705 for the three months ended September 30, 2025, an increase from a net loss of $2,407,829 in the pr
• Cadrenal Therapeutics Files 8-K on Security Holder Votes — 8-K · Sep 24, 2025 Risk: low
  Cadrenal Therapeutics, Inc. filed an 8-K on September 24, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain sp
• 8-K Filing — 8-K · Sep 15, 2025
• Cadrenal's Q2 Loss Widens to $4.5M Amid Tecarfarin Development — 10-Q · Aug 11, 2025 Risk: high
  Cadrenal Therapeutics, Inc. (CVKD) reported no revenue for the quarter ended June 30, 2025, consistent with its status as a clinical-stage pharmaceutical compan
• Cadrenal Therapeutics Files 8-K — 8-K · Aug 5, 2025 Risk: medium
  Cadrenal Therapeutics, Inc. filed an 8-K on August 5, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specif
• Cadrenal Sets Sept. 24 Annual Meeting, Seeks Director Election, Auditor Ratification — DEF 14A · Jul 31, 2025 Risk: low
  Cadrenal Therapeutics, Inc. (CVKD) filed a Definitive Proxy Statement (DEF 14A) on July 31, 2025, for its Annual Meeting of Stockholders scheduled for September
• Cadrenal Therapeutics Reports Director/Officer Changes & More — 8-K · Jul 18, 2025 Risk: medium
  Cadrenal Therapeutics, Inc. filed an 8-K on July 18, 2025, reporting events as of July 15, 2025. The filing indicates changes related to directors and officers,
• Cadrenal Therapeutics Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  Cadrenal Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Delaware with its principa
• Cadrenal Therapeutics Files 8-K — 8-K · Apr 17, 2025 Risk: low
  Cadrenal Therapeutics, Inc. filed an 8-K on April 17, 2025, reporting other events and financial statements. The filing does not contain specific details about
• Cadrenal Therapeutics Files 2024 Annual Report — 10-K · Mar 13, 2025 Risk: medium
  Cadrenal Therapeutics, Inc. filed its annual report for the fiscal year ended December 31, 2024. The company, incorporated in Delaware and headquartered in Pont
• Cadrenal Therapeutics Files 8-K: Material Agreement & Other Events — 8-K · Mar 4, 2025 Risk: medium
  On March 3, 2025, Cadrenal Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statement
• Cadrenal Therapeutics Files 8-K on Executive Changes — 8-K · Feb 7, 2025 Risk: low
  On February 4, 2025, Cadrenal Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing also include
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Cadrenal Therapeutics Files Q3 2024 10-Q Report — 10-Q · Nov 7, 2024 Risk: low
  Cadrenal Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2024. The company, incorporated in Delaware, is involved
• Cadrenal Therapeutics Files 8-K: Agreements, Equity Sales, and More — 8-K · Nov 4, 2024 Risk: medium
  On November 1, 2024, Cadrenal Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company al
• Cadrenal Therapeutics Files 8-K Report — 8-K · Oct 24, 2024 Risk: low
  On October 24, 2024, Cadrenal Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events a
• SC 13G Filing — SC 13G · Oct 4, 2024
• Cadrenal Therapeutics Files 8-K — 8-K · Sep 25, 2024 Risk: medium
  Cadrenal Therapeutics, Inc. filed an 8-K on September 25, 2024, to report on several events. The filing includes information related to Regulation FD disclosure
• Cadrenal Therapeutics Faces Delisting Concerns — 8-K · Sep 5, 2024 Risk: high
  Cadrenal Therapeutics, Inc. filed an 8-K on September 5, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is in
• Cadrenal Therapeutics Acquires Subsidiary Cadrenal Biologics — 8-K · Aug 20, 2024 Risk: low
  Cadrenal Therapeutics, Inc. announced on August 19, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of its subsidiary, C
• Cadrenal Therapeutics Files 8-K — 8-K · Aug 16, 2024 Risk: medium
  Cadrenal Therapeutics, Inc. filed an 8-K on August 16, 2024, to report material modifications to the rights of security holders and other events. The filing ind
• Cadrenal Therapeutics Files 8-K with Financial Updates — 8-K · Aug 8, 2024 Risk: low
  On August 7, 2024, Cadrenal Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and
• Cadrenal Therapeutics Files Q2 2024 10-Q Report — 10-Q · Aug 7, 2024 Risk: medium
  Cadrenal Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2024. The company, incorporated in Delaware with its principal
• Cadrenal Therapeutics Files 8-K Report — 8-K · Aug 6, 2024 Risk: low
  On August 6, 2024, Cadrenal Therapeutics, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also included Financial Sta
• Cadrenal Therapeutics Appoints New CMO, Elects Directors — 8-K · Jul 31, 2024 Risk: medium
  Cadrenal Therapeutics, Inc. announced on July 29, 2024, the appointment of Dr. David J. Recker as Chief Medical Officer and the election of Dr. Recker and Ms. J
• Cadrenal Therapeutics Files Proxy Materials — DEFA14A · Jun 12, 2024 Risk: low
  Cadrenal Therapeutics, Inc. filed definitive additional materials on June 12, 2024, related to its proxy statement. The filing concerns the company's operations
• Cadrenal Therapeutics Files Definitive Proxy Statement — DEF 14A · Jun 11, 2024 Risk: low
  Cadrenal Therapeutics, Inc. filed its definitive proxy statement on June 11, 2024, for its annual meeting on July 29, 2024. The company, located at 822 A1A Nort
• Cadrenal Therapeutics, Inc. Files 10-Q for Period Ended March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  Cadrenal Therapeutics, Inc. (CVKD) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Cadrenal Therapeutics, Inc. filed a Form 10-Q for the quarterly
• Cadrenal Therapeutics Files 8-K with Financials — 8-K · Apr 9, 2024 Risk: low
  On April 9, 2023, Cadrenal Therapeutics, Inc. filed an 8-K report detailing its financial statements and exhibits. The company, incorporated in Delaware, is inv
• Cadrenal Therapeutics Enters Material Definitive Agreement — 8-K · Mar 12, 2024 Risk: medium
  On March 11, 2024, Cadrenal Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related
• Cadrenal Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Mar 11, 2024 Risk: low
  Cadrenal Therapeutics, Inc. (CVKD) filed a Annual Report (10-K) with the SEC on March 11, 2024. Cadrenal Therapeutics, Inc. filed its annual report on Form 10-K
• Cadrenal Therapeutics Faces Delisting Notice — 8-K · Mar 5, 2024 Risk: high
  Cadrenal Therapeutics, Inc. filed an 8-K on March 5, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is also f
• Cadrenal Therapeutics Amends 8-K on Delisting Notice — 8-K/A · Feb 15, 2024 Risk: high
  Cadrenal Therapeutics, Inc. filed an 8-K/A Amendment No. 1 on February 15, 2024, related to an event on September 6, 2023. The filing addresses a Notice of Deli
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Cadrenal Therapeutics (CVKD) Confirms Nasdaq Listing in 8-K Filing — 8-K · Feb 12, 2024 Risk: low
  Cadrenal Therapeutics, Inc. (CVKD) filed an 8-K on February 12, 2024, reporting an event that occurred on February 6, 2024. This filing primarily updates the co

Risk Profile

Risk Assessment: Of CVKD's 37 recent filings, 6 were flagged as high-risk, 14 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Cadrenal Therapeutics, INC.'s most recent 10-K filing (Mar 31, 2026):

• Revenue: N/A
• Net Income: N/A
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: N/A
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Quang Pham
• Leslie Marlow, Esq.
• Patrick Egan, Esq.
• Melissa Palat Murawsky, Esq.
• Dr. Michael L. R. Freeman
• Chief Executive Officer
• Class III director
• Dr. David J. Recker
• Ms. Jennifer L. Johnson

Industry Context

Cadrenal Therapeutics operates in the biopharmaceutical sector, focusing on the development of novel therapies for life-threatening immune and thrombotic conditions. The market for anticoagulants and treatments for immune-mediated disorders is competitive, with significant ongoing research and development by both large pharmaceutical companies and smaller biotech firms. Key trends include the pursuit of targeted therapies with improved safety profiles and the development of treatments for rare or underserved conditions, such as HIT.

Top Tags

filing (7) · corporate-governance (5) · regulatory-filing (4) · 8-K (4) · 10-Q (4) · financials (3) · SEC Filing (3) · quarterly-report (3) · pharmaceuticals (3) · disclosure (3)

Key Numbers

• iXBRL 8-K Size: 44599 — Size of the main 8-K filing document in bytes.
• EX-4.1 Size: 107756 — Size of the 'FORM OF NEW WARRANT' exhibit in bytes.
• EX-4.2 Size: 107728 — Size of the 'FORM OF PLACEMENT AGENT WARRANT' exhibit in bytes.
• EX-10.1 Size: 52845 — Size of the 'FORM OF WARRANT INDUCEMENT AGREEMENT' exhibit in bytes.
• Market Value of Non-Affiliate Common Equity: $24.9M — As of June 30, 2025, indicating current market valuation for public float.
• Common Stock Shares Outstanding: 2.5M — As of March 27, 2026, reflecting the current share count.
• Veralox Asset Acquisition Date: December 10, 2025 — Marks the strategic shift to the 12-LOX platform and CAD-1005.
• End-of-Phase 2 Meeting with FDA: March 26, 2026 — Clarified registrational path for CAD-1005 Phase 3 trial.
• Shares of Common Stock: 428,227 — Aggregate shares offered for resale by Selling Stockholders, from which the company receives no proceeds.
• Common Warrant Shares: 414,748 — Shares issuable upon exercise of Common Warrants from the Private Placement, part of the resale.
• Placement Agent Warrant Shares: 13,479 — Shares issuable upon exercise of Placement Agent Warrants, part of the resale.
• Closing Price per Share: $7.535 — Closing price of CVKD on Nasdaq Capital Market on December 22, 2025.
• Patients with HIT: 5% — Up to 5% of patients exposed to heparin can develop HIT, which VLX-1005 targets.
• SEC File Number: 001-41596 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 88-0860746 — Company's tax identification number.

Forward-Looking Statements

• {"claim":"Cadrenal Therapeutics will maintain its listing on The Nasdaq Stock Market.","entity":"Cadrenal Therapeutics, Inc.","targetDate":"Ongoing","confidence":"high"}

Related Companies

CADL · CADR · CADX · CADRN

Frequently Asked Questions